If you’ve ever had a patient with class III obesity and multiple comorbidities, the answer has historically been surgery. But surgery comes at the cost of procedural risk, nutritional consequences, and limited accessibility.
Retatrutide weight management research now suggests pharmacological weight loss may be approaching surgical territory. The phase 2 trial reported mean reductions of 24.2% at 48 weeks on the 12 mg dose, the highest ever recorded for an investigational anti-obesity medication.
But efficacy tells only part of the story.
The triple agonist mechanism of retatrutide comes with both opportunities and questions. Increased energy expenditure comes with increased heart rate, and as with any novel agent, the gap between phase 2 promise and phase 3 reality remains to be closed.
So what’s the actual science here? Not the commercial speculation, but the peer-reviewed mechanisms and trial data that matter for clinical decision-making?
In this article, we’ll walk through current retatrutide clinical research, where the efficacy data stands, and what questions remain unanswered.
Key Takeaways
- Retatrutide is a triple hormone agonist that targets GLP-1, GIP, and glucagon receptors at once.
- Phase 2 trial data published in NEJM shows that retatrutide leads to dose-dependent weight reduction up to 24.2% at 48 weeks.
- Phase 3 cardiovascular outcome trials are now underway, which will affect the drug’s place in obesity treatment processes.
What Is Retatrutide, and How Does It Work?
Retatrutide is a triple hormone agonist developed by Eli Lilly and Company that activates three metabolically relevant receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon.1, 6
Compared to the body’s natural hormones, retatrutide is engineered to be about nine times more potent at the GIP receptor, while its activity at the GLP-1 and glucagon receptors is more attenuated.7
This means retatrutide targets both sides of the energy balance equation: what goes in (calories) and what goes out (energy used).3
What Do Retatrutide Clinical Trials Show for Weight Management?
The evidence base for retatrutide in weight management rests primarily on a single well-designed phase 2 trial, though phase 3 programs are now actively underway.
The phase 2 trial enrolled 338 adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related complication, like hypertension, dyslipidemia, cardiovascular disease, or obstructive sleep apnea (OSA).⁴
Participants were randomized to once-weekly subcutaneous retatrutide (1 mg, 4 mg, 8 mg, or 12 mg), placebo, or an active comparator (dulaglutide 1.5 mg). The trial included a 48-week treatment period with a four-week safety follow-up and led to three substudies:
- The MASLD substudy looked at the effect on liver fat in patients with MASLD.10
- The body composition substudy used DEXA scans to measure changes in fat and lean mass in patients with type 2 diabetes.7
- The qualitative exit interview study considered detailed patient experiences of life on the medication.8
Based on these studies, here’s how retatrutide affects weight management:
1. Weight Reduction Outcomes
At 48 weeks in the main obesity trial, retatrutide led to the following dose-dependent weight reductions:
- 4 mg (combined) led to 17.1% mean weight loss
- 8 mg (combined) led to 22.8% mean weight loss
- 12 mg led to 24.2% mean weight loss
- Placebo averaged 2.1% mean weight loss⁴
These results were even more pronounced in the MASLD substudy, where the 12 mg group achieved a mean weight reduction of 25.9% at 48 weeks.10
In the main trial, the 12 mg dose resulted in 100% of patients reaching ≥5% weight loss, 93% achieving ≥10%, 83% reaching ≥15%, and 63% achieving ≥20% weight loss.4
Weight loss continued through the full 48 weeks without plateauing in the 8 mg and 12 mg groups. This suggests that longer treatment duration might lead to additional effects.4
2. Weight Reduction Outcomes in Type 2 Diabetes
The separate phase 2 trial in patients with type 2 diabetes showed significant weight reductions, though slightly less than in the non-diabetic population:
| Dose | Body Weight Reduction at 36 Weeks |
| Placebo | 3.00% |
| Dulaglutide 1.5 mg | 2.02% |
| Retatrutide 12 mg (escalation) | 16.94% |
Retatrutide 12 mg led to 16.94% weight reduction at 36 weeks in patients with type 2 diabetes, compared to 2.02% with dulaglutide and 3.00% with placebo.5,9
This shows that retatrutide is highly effective for weight management even in a population where weight loss is usually more challenging.
3. Weight Loss Targets
A 2025 meta-analysis pooled data across trials and found that retatrutide led to much higher odds of reaching weight loss targets compared to placebo:
| Weight Loss Target | Odds Ratio vs. Placebo (95% CI) | P-value |
| ≥5% weight loss | 43.34 (25.81 to 72.77) | <0.00001 |
| ≥10% weight loss | 89.84 (42.31 to 190.77) | <0.00001 |
| ≥15% weight loss | 46.93 (20.59 to 106.98) | <0.00001 |
Patients taking retatrutide are 43 times more likely to lose at least 5% of their body weight and 90 times more likely to lose at least 10% compared to placebo.
The slightly lower odds ratio for ≥15% compared to ≥10% means that reaching very high weight loss targets is more challenging, but retatrutide’s effects remain extremely strong.9
4. Weight Lost by Subgroup
The phase 2 trial by Jastreboff and colleagues conducted prespecified subgroup analyses that found important differences in treatment response.4 When looking at baseline BMI:
- Participants with BMI ≥35 kg/m² lost more weight than those with BMI <35 kg/m²
- 8 mg (4 mg starting dose) led to 26.5% vs. 21.3% weight reduction
- 12 mg led to 26.4% vs. 21.5% weight reduction
When dividing by sex:
- Women lost more weight than men across all dose groups
- 8 mg (4 mg starting dose) led to 28.5% in women vs. 19.8% in men
- 12 mg led to 26.6% in women vs. 21.9% in men
However, the trial enrolled approximately equal numbers of men and women (with 51.8% men), which may have reduced the overall efficacy results compared to trials with higher female representation.4
5. Waist Circumference Reduction
Waist circumference is a key marker of abdominal obesity and cardiometabolic risk. It was significantly reduced across all retatrutide clinical research trials.
In the main obesity trial, reductions ranged from -6.5 cm to -19.6 cm with retatrutide vs. -2.6 cm with placebo at 48 weeks.4 Similarly, in the MASLD substudy, absolute reductions ranged from 6.1 cm to 20.6 cm.10
In a 2023 randomized trial, waist circumference reductions were consistent with the above, with the 12 mg dose leading to the largest effects.5
6. Body Composition Changes
The body composition substudy, which used DEXA scanning in patients with type 2 diabetes, provided the most detailed look at where the weight is lost.7
At 36 weeks, total fat mass was reduced by 23.2% in the 12 mg group and 26.1% in the 8 mg group, compared to just 4.5% with placebo. When compared to an active control (dulaglutide 1.5 mg), the fat loss with retatrutide 8 mg was greater (-26.1% vs. -2.6%).
Approximately 70% of the weight lost came from fat mass, with the remainder from lean mass. The proportion of lean mass loss to total weight loss was also similar to other obesity treatments, which meant the weight reduction did not come at the cost of muscle wasting.7
In fact, the MASLD substudy found that retatrutide significantly reduced both visceral adipose tissue (VAT) and abdominal subcutaneous adipose tissue (ASAT) in a dose-dependent manner, with effects becoming more pronounced at 48 weeks.10
Near-maximal liver fat reduction was achieved at approximately 40% reductions in both VAT and ASAT. This suggests that hepatic fat is reduced early in treatment.10
7. Weight Regain After Discontinuation
The MASLD substudy provided the only data on what happens when treatment stops. At the safety follow-up visit, about four weeks after the last dose, the researchers noted “some” weight regain.10
This matches the known pharmacology of incretin-based therapies, including this GLP-1-GIP-glucagon therapy, where weight loss effects are treatment-dependent.
What About Safety and Tolerability?
The most common adverse events of retatrutide were gastrointestinal, with most events being mild to moderate and occurring during dose escalation. They included:
- Nausea
- Diarrhea
- Vomiting
- Constipation
Unlike GLP-1 agonists, which may slightly reduce heart rate, retatrutide was associated with dose-dependent increases in resting heart rate.
Mean increases ranged from four to eight beats per minute in the 8-12 mg groups, with the increase occurring early and persisting through treatment.⁴
What Are the Current Limitations of Retatrutide Clinical Research?
The retatrutide literature is promising, but it’s not where we need it to be yet. Here are its limitations:
- Phase 3 data not yet available. The efficacy results from phase 2 are strong, but we don’t yet have the large-scale cardiovascular outcome trials that will define the safety profile for chronic use.
- Durability unknown. Weight loss continued through 48 weeks without a plateau. Whether this suggests a continued effect or simply a delayed plateau isn’t clear. Longer-term data is needed to set clinical expectations.
- Heart rate increases. The four to eight bpm heart rate increase is mechanistically interesting but clinically concerning. We need cardiovascular outcome data to understand whether this means increased risk or is a benign adaptive response.
Source Weight Management Treatments from Medica Depot
If you’ve read this far, you understand that retatrutide may lead to a potential change in pharmacological weight management. But the variables in research are many, and one you shouldn’t have to worry about is whether your materials are what they claim to be.
At Medica Depot, we supply genuine, brand-name products to medical professionals who need reliability they can count on. Every product comes with original LOT numbers, and our team is available to confirm batch information whenever needed.
We work with licensed distributors to ensure authenticity while keeping pricing competitive. Through our price match program, loyalty benefits, referral rewards, and regular monthly discounts, you can get high-quality medical supplies at some of the most competitive prices available.
Contact Medica Depot today to learn more about available products and pricing for your practice.
FAQs
Does Retatrutide Improve Outcomes Beyond Weight Loss?
Yes. Phase 2 data showed improvements in:
- Systolic blood pressure, which was reduced by 10 to 15 mmHg
- Triglycerides, which fell by 40-50%
- Insulin resistance, which improved by up to 69% with higher doses
- Prediabetes remission, where 72% of participants with prediabetes at baseline reverted to normoglycemia with retatrutide treatment, compared to 22% with placebo
These effects likely show direct receptor-mediated metabolic health improvements, especially from GIP and glucagon activation.
How Does Retatrutide Compare to Ozempic, Wegovy, and Mounjaro?
Retatrutide is still investigational, but phase 2 data shows 24.2% weight loss at 48 weeks with the 12 mg dose.
In comparison, clinical trials of semaglutide (Wegovy) show about 15% to 17% weight loss at 68 weeks, while tirzepatide (Mounjaro) causes 20% to 22% weight loss at 72 weeks.
Is Retatrutide Approved for Clinical Use?
No. Retatrutide is investigational and not FDA-approved for any indication. It is currently in phase 3 clinical trials. Any use outside of registered clinical trials is not supported by efficacy or safety data.
References
1. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013
2. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. doi:10.1016/S0140-6736(22)02033-5
3. Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201-223. doi:10.1038/s41573-021-00337-8
4. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
5. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1, and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. doi:10.1016/S0140-6736(23)01053-X
6. ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1). NCT05929066. Updated 2025.
7. Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025;13(8):674-684. doi:10.1016/S2213-8587(25)00092-0
8. Goetz IA, Kanu C, Hoover A, et al. Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial. Obes Pillars. 2025;16:100220. Published 2025 Oct 24. doi:10.1016/j.obpill.2025.100220
9. Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Proc (Bayl Univ Med Cent). 2025;38(3):291-303. Published 2025 Feb 5. doi:10.1080/08998280.2025.2456441
10. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. doi:10.1038/s41591-024-03018-2
